Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 14, 2019

SELL
$2.82 - $4.67 $6,401 - $10,600
-2,270 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$1.45 - $6.15 $3,291 - $13,960
2,270 New
2,270 $10,000

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $185M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Signet Financial Management, LLC Portfolio

Follow Signet Financial Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Signet Financial Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signet Financial Management, LLC with notifications on news.